Get started
Author

Neil J. Hounslow

Observed names: N Hounslow, N. Hounslow, N. J. Hounslow, N.J. Hounslow, NJ Hounslow, Neil Hounslow
ORCID: 0000-0002-9821-4941
Observed ORCID: 0000-0002-9821-4941
OpenAlex ID: A5032552822
Pregabalin Drug Interaction Studies: Lack of Effect on the Pharmacokinetics of Carbamazepine, Phenytoin, Lamotrigine, and Valproate in Patients with Partial Epilepsy
2005 · Martin J. Brodie, Elaine A. Wilson, et al. · Epilepsia · 123
Effect of Age and Gender on Pharmacokinetics of Atorvastatin in Humans
1996 · Donald M. Gibson, Nicola J. Bron, et al. · The Journal of Clinical Pharmacology · 90
Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia
2009 · Leiv Ose, Dragos Budinski, et al. · Current Medical Research and Opinion · 85
Pharmacodynamics and Pharmacokinetic-Pharmacodynamic Relationships of Atorvastatin, an HMG-CoA Reductase Inhibitor
2000 · Ralph H. Stern, Bing‐Bing Yang, et al. · The Journal of Clinical Pharmacology · 82
Comparative long‐term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20–40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia
2011 · J. Gumprecht, M. Gosho, et al. · Diabetes Obesity and Metabolism · 80
Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia
2009 · Dragos Budinski, Valerie Arneson, et al. · Clinical Lipidology · 68
Statin action favors normalization of the plasma lipidome in the atherogenic mixed dyslipidemia of MetS: potential relevance to statin-associated dysglycemia
2015 · Peter J. Meikle, Gerard Wong, et al. · Journal of Lipid Research · 65
PDF
Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia
2009 · Leiv Ose, Dragos Budinski, et al. · Atherosclerosis · 59
Efficacy and Safety of Pitavastatin in Children and Adolescents at High Future Cardiovascular Risk
2015 · Marjet J.A.M. Braamskamp, Claudia Stefanutti, et al. · The Journal of Pediatrics · 52
Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy
2022 · Henry N. Ginsberg, Neil J. Hounslow, et al. · Diabetes Care · 48
PDF
Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: insights from the CAPITAIN and PREVAIL-US studies
2013 · M. J. Chapman, A. Orsoni, et al. · Current Medical Research and Opinion · 45
Pitavastatin shows greater lipid-lowering efficacy over 12 weeks than pravastatin in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia
2012 · Steen Stender, Dragos Budinski, et al. · European Journal of Preventive Cardiology · 37
Comparative efficacy of pitavastatin and simvastatin in high-risk patients: a randomized controlled trial
2011 · Mats Eriksson, Dragos Budinski, et al. · Advances in Therapy · 37
PDF
Drug Interactions with Clinafloxacin
2001 · Edward J. Randinitis, Christine W. Alvey, et al. · Antimicrobial Agents and Chemotherapy · 29
Long-term efficacy of pitavastatin versus simvastatin
2011 · Mats Eriksson, Dragos Budinski, et al. · Advances in Therapy · 28
PDF
Comparison of the Pharmacokinetics of Pitavastatin by Formulation and Ethnic Group: An Open-Label, Single-Dose, Two-Way Crossover Pharmacokinetic Study in Healthy Caucasian and Japanese Men
2011 · Steve Warrington, Shunji Nagakawa, et al. · Clinical Drug Investigation · 26
Pitavastatin demonstrates long-term efficacy, safety and tolerability in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia
2012 · Steen Stender, Dragos Budinski, et al. · European Journal of Preventive Cardiology · 21
Pemafibrate Has High Bioavailability and is Principally Excreted via the Liver
2018 · Neil Hounslow, Stuart Mair, et al. · Atherosclerosis Supplements · 17
Abstract: P770 ROBUST EFFICACY OF PITAVASTATIN AND COMPARABLE SAFETY TO PRAVASTATIN
2009 · S Stender, N Hounslow · Atherosclerosis Supplements · 14
Effects of Atorvastatin, an HMG‐CoA Reductase Inhibitor, on Hepatic Oxidative Metabolism of Antipyrine
1996 · Bing‐Bing Yang, Neil J. Hounslow, et al. · The Journal of Clinical Pharmacology · 14
Pitavastatin Concentrations Are Not Increased by CYP3A4 Inhibitor Itraconazole in Healthy Subjects
2013 · Shunji Nakagawa, Masahiko Gosho, et al. · Clinical Pharmacology in Drug Development · 12
Pemafibrate Minimally Affected the Systemic Exposure of Statins, and Vice Versa, in Healthy Male Volunteers
2018 · Neil Hounslow, Hideki Suganami, et al. · Atherosclerosis Supplements · 10
Clinafloxacin Pharmacokinetics in Subjects with Various Degrees of Renal Function
2001 · Edward J. Randinitis, Jeffery R. Koup, et al. · Antimicrobial Agents and Chemotherapy · 10
Pitavastatin therapy in polymedicated patients is associated with a low risk of drug-drug interactions: analysis of real-world and phase 3 clinical trial data
2015 · Masahiko Gosho, Masaya Tanahashi, et al. · International Journal of Clinical Pharmacology and Therapeutics · 9
MS389 PITAVASTATIN 4 mg SHOWS COMPARABLE LDL-CHOLESTEROL AND SUPERIOR TRIGLYCERIDE REDUCTION TO SIMVASTATIN 40 mg IN HIGH-RISK PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPIDEMIA
2010 · N. Hounslow, D. Budinski, et al. · Atherosclerosis Supplements · 9
Works count: 47
Citation count: 1,109
H-index: 17
I10-index: 23
Year
Topic
Type